Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H19N5O6S2 |
Molecular Weight | 453.493 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=C/CC)\C3=CSC(N)=N3)C(O)=O
InChI
InChIKey=HJJRIJDTIPFROI-NVKITGPLSA-N
InChI=1S/C17H19N5O6S2/c1-2-3-8(9-6-30-16(18)20-9)12(23)21-10-13(24)22-11(15(25)26)7(4-28-17(19)27)5-29-14(10)22/h3,6,10,14H,2,4-5H2,1H3,(H2,18,20)(H2,19,27)(H,21,23)(H,25,26)/b8-3-/t10-,14-/m1/s1
Molecular Formula | C17H19N5O6S2 |
Molecular Weight | 453.493 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/8107269Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18347113 | https://www.ncbi.nlm.nih.gov/pubmed/26440444
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8107269
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18347113 | https://www.ncbi.nlm.nih.gov/pubmed/26440444
Cefcapene is a semisynthetic third-generation cephalosporin with antibacterial activity. Cefcapene binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P02918 Gene ID: 947907.0 Gene Symbol: mrcA Target Organism: Escherichia coli (strain K12) |
|||
Target ID: CHEMBL3512 |
|||
Target ID: CHEMBL2725 |
2.0 nM [Ki] | ||
Target ID: CHEMBL2363020 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://www.ndrugs.com/?s=giasion |
Curative | Giasion Approved UseGIASION is indicated for treatment of the following infections caused by susceptible microorganisms: (see section 5.1 pharmacodynamic properties):
Pharyngo-acute tonsillitis
Acute maxillary sinusitis
Acute exacerbation of chronic bronchitis
Community acquired pneumonia, mild or moderate
Infections uncomplicated skin and skin structures, such as cellulitis, wound infections, abscesses, folliculitis, impetigo and boils. |
||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26440444
Oral antibiotic therapy (CFPN-PI (CEFCAPENE), 300 mg/day) were started, resulting in gradual improvement
of the skin lesion to a PPPASI score of 1 and a VAS score of 2.2 after 2 months
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18347113
A spontaneous rifampin-resistant H. influenzae Rd clone, designated RdRIF (19), and two BLNAR isolates (MSC06647 and MSC06663) were used in this study.
Cefcapene activity was determined by the broth dilution method. Cefcapene shows potent antimicrobial activity with MIC 0.008mg/ml (for RdRIF), 0.25mg/ml (for MSC06647) and 2 mg/ml (for MSC06663).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:39:10 GMT 2023
by
admin
on
Fri Dec 15 16:39:10 GMT 2023
|
Record UNII |
4D5D3422MW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
||
|
WHO-ATC |
J01DD17
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
||
|
WHO-VATC |
QJ01DD17
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m3190
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL582912
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
PRIMARY | |||
|
C76160
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
PRIMARY | |||
|
SUB07383MIG
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
PRIMARY | |||
|
4159
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
PRIMARY | |||
|
135889-00-8
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
PRIMARY | |||
|
4D5D3422MW
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
PRIMARY | |||
|
DB13461
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
PRIMARY | |||
|
7006
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
PRIMARY | |||
|
DTXSID201027544
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
PRIMARY | |||
|
6436055
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
PRIMARY | |||
|
100000081795
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
PRIMARY | |||
|
CEFCAPENE
Created by
admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |